DJIA 17,817.90 7.84 0.04%
NASDAQ 4,754.89 41.92 0.89%
S&P 500 2,069.41 5.91 0.29%
market minute promo

MannKind Corp (NASDAQ: MNKD)



company name or ticker

Short Interest in Biotech Becomes Company Specific

MannKind: A Very Favorable Risk/Reward Profile

Why Is Sanofi Betting on MannKind Corporation's Afrezza?

Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?

MannKind Receives $150 Million Upfront Payment from Sanofi - Analyst Blog

Is It Time to Buy Top Dividend Stock Sanofi?

French biopharma Sanofi offers one of the highest-dividend yields in the healthcare sector. But is the stock a buy?

MannKind Reality Check

With Ebola Looming, When Will The Defense Department Get Around To Generex?

MannKind and Sanofi Complete Afrezza Collaboration Deal - Analyst Blog

Sanofi Vs. MannKind - Afrezza Is Better For Sanofi

MannKind Corp Becomes Oversold

See More Articles...